Jade Biosciences, Inc. (JBIO)
| Market Cap | 1.27B |
| Revenue (ttm) | n/a |
| Net Income | -102.34M |
| EPS | -2.27 |
| Shares Out | 49.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 697,493 |
| Open | 23.82 |
| Previous Close | 24.22 |
| Day's Range | 23.82 - 26.61 |
| 52-Week Range | 6.57 - 28.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 31.20 (+20.88%) |
| Earnings Date | May 7, 2026 |
About JBIO
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for JBIO stock is "Strong Buy." The 12-month stock price target is $31.2, which is an increase of 20.88% from the latest price.
News
Jade Biosciences files $600M mixed securities shelf
17:17 EDT Jade Biosciences (JBIO) files $600M mixed securities shelf
Jade Biosciences files to sell 39.54M shares of common stock for holders
17:22 EDT Jade Biosciences (JBIO) files to sell 39.54M shares of common stock for holders
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
SAN FRANCISCO and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-c...
Jade Biosciences price target raised to $45 from $35 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Jade Biosciences (JBIO) to $45 from $35 and keeps a Buy rating on the shares. The company is set to report data
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on dev...
Jade Biosciences appoints Edward Conner as chief medical officer
Jade Biosciences (JBIO) announced the appointment of Edward Conner as chief medical officer, effective immediately. Conner joins Jade from Ardelyx (ARDX) where he served as CMO.
Jade Biosciences Appoints Edward R. Conner, M.D.
SAN FRANCISCO and VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on dev...
Jade Biosciences price target raised to $35 from $25 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Jade Biosciences (JBIO) to $35 from $25 and keeps a Buy rating on the shares following the Q4 report. The firm increased
Jade Biosciences participates in a conference call with William Blair
Analyst Matt Phipps holds a conference call with management on March 19 at 2:15 pm hosted by William Blair. Webcast Link
Jade Biosciences price target raised to $39 from $28 at BTIG
BTIG raised the firm’s price target on Jade Biosciences (JBIO) to $39 from $28 and keeps a Buy rating on the shares. The firm is positive on the company’s potential
Jade Biosciences Transcript: Leerink Global Healthcare Conference 2026
The company is advancing a best-in-class anti-APRIL antibody for IgA nephropathy, aiming for less frequent dosing and superior efficacy, with phase I data expected soon and rapid progression to phase II. Market research highlights strong demand for extended dosing intervals, and the pipeline includes additional autoimmune programs and expansion opportunities.
Jade Biosciences price target raised to $23 from $17 at Guggenheim
Guggenheim raised the firm’s price target on Jade Biosciences (JBIO) to $23 from $17 and keeps a Buy rating on the shares ahead of “key” Phase 1 JADE101 data next
Jade Biosciences price target raised to $40 from $19 at Stifel
Stifel analyst Alex Thompson raised the firm’s price target on Jade Biosciences (JBIO) to $40 from $19 and keeps a Buy rating on the shares following the Q4 report. The
Jade Biosciences initiated with an Outperform at LifeSci Capital
LifeSci Capital analyst Rami Katkhuda initiated coverage of Jade Biosciences (JBIO) with an Outperform rating and $24 price target
Jade Biosciences reports Q4 EPS ($3.19), consensus ($2.95)
Tom Frohlich, Chief Executive Officer of Jade Biosciences (JBIO), commented: “We closed 2025 with strong momentum, having initiated the JADE101 Phase 1 healthy volunteer study, continued to advance JA...
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
SAN FRANCISCO and VANCOUVER, British Columbia, March 06, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in...
Jade Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
Three antibody programs are advancing, with JADE101 targeting IgA nephropathy and phase I data expected 1H 2024. The company is focused on best-in-class efficacy, convenient dosing, and robust biomarker-driven development, with a strong cash position and potential for accelerated regulatory pathways.
Jade Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The presentation highlighted a robust pipeline targeting autoimmune diseases, with JADE101 poised for key data in IgA nephropathy and JADE201 advancing into clinical trials for broader autoimmune indications. Strong financials support rapid development and multiple upcoming milestones.
Jade Biosciences to Participate in Upcoming Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies ...
Jade Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company is advancing a pipeline of best-in-class autoimmune therapeutics, led by JADE101 for IgA nephropathy, aiming for superior efficacy and convenience. With strong financial backing and experienced leadership, it targets large, expanding markets and plans rapid clinical progression.
Jade Biosciences initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Jade Biosciences (JBIO) with a Buy rating and $25 price target The firm believes the company is a well positioned to become a leader in
Jade Biosciences outlines key 2026 objectives, strategy
Jade Biosciences (JBIO) announced its 2026 strategic priorities, including anticipated milestones ahead of the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San F...
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference
JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mi...
Jade Biosciences files to sell 3.21M shares of common stock for holders
16:39 EST Jade Biosciences (JBIO) files to sell 3.21M shares of common stock for holders
Jade Biosciences prices 3.21M shares at $14.00 in private placement
Jade Biosciences (JBIO) entered into a securities purchase agreement with BB Biotech (BBAGF) for a private placement financing that is expected to result in gross proceeds of approximately $45M to